Aim The aim of this study was to examine the pharmacokinetics of donepezil HCl and cimetidine separately, and in combination, following administration of multiple oral doses.
Introduction
[11] has been confirmed by clinical studies in patients with Alzheimer's disease [12] [13] [14] [15] . In these patients, treatment It is generally accepted that cognitive impairment and memory loss in patients with Alzheimer's disease are related with donepezil was associated with statistically significant improvements in cognition and global function following to the loss of cholinergic pathways in the cerebral cortex and other areas of the brain [1] . As a result, the clinical administration of 5 or 10 mg day −1 doses [13 -15] . The principal adverse events associated with donepezil were development of agents to counteract the symptoms of this disease has focused on those which enhance the function of transient gastrointestinal disturbances, which included abdominal pain, nausea and vomiting, and occurred in a the surviving cholinergic neurones within the affected areas of the central nervous system [1] [2] [3] . Donepezil HCl (also small percentage of patients. All of these events are consistent with an increase in cholinergic stimulation. known as E2020 or AriceptA, the registered trademark of Eisai Co. Ltd, Tokyo, Japan) is the first member of a new
The pharmacokinetics of donepezil in healthy male volunteers are characterized by hepatic metabolism and slow group of acetylcholinesterase inhibitors, the piperidines, that has been developed for the treatment of Alzheimer's disease plasma clearance (0.13 l h −1 kg −1 ) [16, 17] . The long halflife of approximately 70 h means that once-daily drug [4] [5] [6] [7] [8] [9] . Pre-clinical studies using both in vivo and in vitro models indicate that donepezil has a markedly greater administration results in insignificant variability in plasma drug concentrations at steady state. selectivity for acetylcholinesterase (AChE) compared with butyrylcholinesterase (BuChE), and a longer duration of Cimetidine, an H 2 -receptor antagonist, is one of the most widely prescribed drugs for the treatment of duodenal ulcers, inhibitory action than either physostigmine or tacrine [10] .
The dose-related pharmacodynamic activity (AChE heartburn and gastritis. Cimetidine is known to have an inhibitory action on hepatic microsomal enzyme systems and has been shown to impair the metabolism of a number of commonly prescribed drugs, including anticoagulants, phenytoin, propranolol, some benzodiazepines and theophylwere collected at specified intervals up to 120 h. Trough samples were taken each morning prior to drug adminisline [18] . In addition, a recent study has shown that cimetidine significantly affects the pharmacokinetics of tration (i.e. at 24, 48 and 72 h). The subjects returned to the clinic as out-patients for the tacrine HCl [19] , a cholinesterase inhibitor that is approved in the USA, France and Germany for the treatment of next four mornings to provide blood samples for pharmacokinetic analysis and to receive their daily dose of medication. patients with mild-moderate Alzheimer's disease. As a consequence, clinical consideration must be given to They were re-admitted to the study site on the evening of day 6 and repeated the same schedule of events as on day 0. reducing the dose of tacrine when it is co-administered with cimetidine.
The subjects were discharged from the study site on the morning of day 8, 24 h after receiving their final dose of As donepezil is predominantly metabolized by the hepatic CYP-450 isoenzyme 3A4, and to a lesser extent 2D6, this medication. They returned to the clinic as out-patients for the next six mornings to provide blood for post-dose study was designed to investigate whether the concurrent administration of donepezil and cimetidine would alter the pharmacokinetic analysis (to 168 h). During the course of the treatment period, subjects were not allowed to consume plasma pharmacokinetic profile of either drug, following single-and multiple-dose administration.
caffeine-containing food or drinks, and physical exercise was limited to normal walking.
Methods

Sample collection and analysis Subjects
Entry into the study was confined to healthy, non-smoking, Venous blood samples for the determination of donepezil and/or cimetidine concentrations in plasma were collected male volunteers between 18 and 45 years of age who were within 20% of ideal body weight, based on the Metropolitan during each treatment period. Samples were collected 1 h prior to drug administration, and at 0. Immediately after collection, the blood samples were ties were specifically excluded from the study, as were those who had a known or suspected history of alcohol or drug placed on ice and centrifuged for 15 min (2000 g at 4°C). Plasma was then removed and transferred into polypropylene misuse or a positive urine drug screen. None of the subjects had donated blood or had received investigational or tubes which were stored upright at −20°C until analysis. Plasma concentrations of donepezil (hydrochloride salt) were prescription medications within 1 month of commencing trial medication.
determined using a specific high-performance liquid chromatography (HPLC) method with UV detection [20] . The study was conducted in accordance with the principles stated in the Declaration of Helsinki, and the Cimetidine was analysed using a standard reversed-phase HPLC method with UV detection. The limits of detection protocol was approved by the Institutional Review Board for Investigations Involving Human Subjects, Harris for these assays were 2 ng ml −1 for donepezil and 0.1 mg ml −1 for cimetidine. Laboratories, Lincoln, Nebraska, USA. All subjects gave written informed consent prior to participation in the study.
Pharmacokinetic assessments Protocol
This was an open-label, randomized, three-period crossover Characterization of donepezil and/or cimetidine pharmacokinetics for each treatment phase was done by analysing study. The three randomized treatments administered in this study were (1) donepezil HCl, 5 mg tablet, (2) cimetiblood samples collected over a 120-h period following initial dose administration, and a 168-h period following final dose dine, 800 mg tablet (TagametA, Burroughs Wellcome Laboratories), and (3) donepezil 5 mg+cimetidine 800 mg.
administration. Pharmacokinetic parameters for both drugs were estimated Each treatment period was 7 days in duration and was followed by a 3-week, drug-free washout period. The dose by a non-compartmental method. Peak plasma concentration (C max ) and the time at which it occurred (t max ) were of donepezil was chosen on the basis of results from clinical efficacy studies conducted in the USA, and the dose of recorded from the observed values, and the terminal disposition phase for donepezil and cimetidine was identified cimetidine is the recommended starting therapeutic dose for treatment provided by the Physicians' Desk Reference.
by visual inspection of each subject's log concentrationtime curve. The terminal disposition rate constant (l z ) was All volunteers were screened by medical history, ECG and laboratory and physical examinations ≤2 weeks prior estimated to be −2.303 times the slope of the best-fit linear regression line of the terminal phase. The terminal half-life to the start of the study. For each treatment period, subjects were admitted to the study site on the evening of day 0, at (t D ) was calculated as 0.693/l z , and the area under the plasma concentration-time curve from 0 to 24 h (AUC (0-24) ) least 12 h prior to drug administration. Subjects were fasted overnight (8 h) prior to receiving their first dose of was estimated using the trapezoidal rule. The accumulation ratio (R A ) was defined as AUC (0-24) on day 7 divided by medication on the morning of day 1. Following drug administration, blood samples for analytical determinations AUC (0-24) on day 1. Mean plasma cimetidine concentrations were calculated per time-point for each cimetidine treatment group (cimetidine All study subjects were Caucasian. The one subject who did not complete the study was withdrawn because he was alone, donepezil+cimetidine). A time-concentration plot of these mean data is presented in Figure 2 . unable to comply with the dosing schedule.
Results of the cimetidine pharmacokinetic analysis are summarized in Table 3 . On day 1, a statistically significant Pharmacokinetics of donepezil difference was observed between C max ( P=0.001) of the cimetidine-only and the donepezil+cimetidine groups. The Mean plasma donepezil concentrations were calculated per time-point for each donepezil treatment group (donepezil latter had a 20% greater C max (4.1 ng ml −1 versus 3.3 ng ml −1 ) than the cimetidine-only group. No statistically alone, donepezil+cimetidine). A time-concentration plot of these data is presented in Figure 1 .
significant difference was observed in any of the other parameters between these groups. On day 1, a statistically significant difference was observed between the donepezil and the donepezil+cimetidine No statistically significant differences were observed between the groups for C max , AUC (0-24) , t D or R A on day 7 groups in terms of C max ( P=0.001) and AUC (0-24) ( P= 0.032). The donepezil+cimetidine group had a 13% greater ( Table 4 ). The cimetidine-only group had a statistically significantly greater t max ( P=0.016) than the combination C max (7.8 ng ml −1 versus 6.8 ng ml −1 ) and a 10% greater AUC (0-24) (112 ng h ml −1 versus 102 ng h ml −1 ) than the group (3.7 h versus 3.1 h, respectively). No significant sequence effects were observed. donepezil-only group (Table 1) . The coefficients of variation were 10.4% and 12.2% for C max and AUC (0-24) , respectively.
All differences observed in the pharmacokinetic parameters of the cimetidine and the donepezil+cimetidine treatment No significant difference was observed between t max of both groups. No significant sequence effects were observed. groups on days 1 and 7 were also well below the range (±20%) suggested for clinical relevance. On day 7, a statistically significant difference was Figure 2 The effect of concomitant administration of donepezil (5 mg ) and cimetidine (800 mg ) once daily for 7 days on the Figure 1 The effect of concomitant administration of donepezil mean (±SE) plasma concentration-time profile of cimetidine in healthy male volunteers: 24-h profiles were conducted following (5 mg ) and cimetidine (800 mg ) once daily for 7 days on the mean (±SE) plasma concentration-time profile of donepezil in dose administration on day 1 and day 7. Concentrations of cimetidine were below the detectable limit, in one or both healthy male volunteers: 24-h profiles were conducted following dose administration on day 1 and day 7.
treatment groups, at 48, 192 and 216 h. Table 3 Cimetidine pharmacokinetic parameters on day 1 (mean±SE). Table 4 Cimetidine pharmacokinetic parameters on day 7 (mean±SE). treatment groups after 7 days of drug administration. This Safety suggests that plasma concentrations of donepezil remain consistent and predictable, and are not changed significantly Both treatments were well tolerated and there were no clinically significant changes in vital signs, clinical laboratory in the presence of cimetidine. Although these results demonstrate that the metabolism or ECG parameters during the course of the study. Those adverse events that were reported were transient and of donepezil is decreased by the presence of cimetidine, it is unclear whether the metabolism of the drug is altered in dissipated with continued drug administration. All were mild to moderate in intensity.
such a way as to produce a changed pattern of metabolites. As the metabolites of donepezil are essentially clinically inactive (due both to low plasma concentrations as well as Discussion an inability to cross the blood-brain barrier), it is unlikely that even a substantial change in the metabolic processing Cimetidine has been shown to reduce the hepatic metabolism of some drugs, including anticoagulants, phenytoin, propranof the drug would result in either a modification of drug effect or an increase in adverse events. olol, some benzodiazepines and theophylline [18] , apparently through the inhibition of hepatic microsomal enzyme Cimetidine pharmacokinetics remained essentially unchanged by the concurrent administration of donepezil. systems. As donepezil is predominantly metabolized in the liver, the concurrent administration of cimetidine might
Although there was a significantly greater C max for the donepezil+cimetidine group on day 1, and a significantly affect the plasma concentration of donepezil.
The concurrent administration of both single and multiple greater t max for the cimetidine-only group on day 7, these changes were inconsistent and there were no specific trends doses of donepezil (5 mg ) and cimetidine (800 mg ) resulted in an increase in the plasma levels of donepezil compared or changes in cimetidine pharmacokinetics between the two treatment groups. This lack of effect on cimetidine with the single-and multiple-dose administration of donepezil alone. This change in donepezil plasma concentration pharmacokinetics was anticipated, and is consistent with the results from in vitro studies with donepezil (AriceptA US was reflected by increases in both C max (11-13%) and AUC (0-24) (10%). There was no difference in the t max values package insert, 1998). Isoform-selective substrate studies were conducted in human liver microsomes and the of the treatment groups on either days 1 or 7. In addition, t D and the rate of donepezil accumulation in plasma were concentrations of donepezil required for 50% inhibition (IC 50 ) of CYP-450 enzymes 1A2, 2C9, 2C19, 2D6 and similar for both the donepezil and the donepezil+cimetidine metabolized by these or any other CYP-450 isoenzymes. will not require a modification in dosing.
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